Introducing GPT-Rosalind for Life Sciences Research
OpenAI has announced GPT-Rosalind, a frontier reasoning model specifically designed for life sciences applications including drug discovery, genomics analysis, protein reasoning, and scientific research workflows. The model represents a domain-specialized deployment of OpenAI's reasoning capabilities targeted at biomedical research. This is a tier-1 lab release with a focused vertical application rather than a general-purpose model launch.
Related guides (4)
Related events (8)
OpenAI introduces GPT-Rosalind with life sciences and biological reasoning capabilities
OpenAI announced GPT-Rosalind, a model or product variant targeting life sciences research with enhanced capabilities in biological reasoning, medicinal chemistry, genomics analysis, and experimental workflow support. The announcement positions this as a domain-specialized offering from OpenAI for scientific research applications. This represents OpenAI's continued push into vertical AI for high-value scientific domains.
OpenAI Launches Rosalind Biodefense Program for Government and Vetted Developer Access
OpenAI has launched Rosalind Biodefense, a program expanding trusted access to GPT-Rosalind for vetted developers and U.S. government partners. The initiative targets biodefense, public health, and pandemic preparedness applications. This represents a structured deployment pathway for frontier AI in high-stakes biosecurity contexts.
OpenAI and Retro Biosciences Deploy GPT-4b micro for Protein Engineering in Longevity Research
OpenAI collaborated with Retro Biosciences to apply a specialized model called GPT-4b micro to protein engineering tasks relevant to stem cell therapy and longevity research. The work represents a concrete application of a fine-tuned or specialized variant of GPT-4 to life sciences, specifically improving protein design effectiveness. This is a notable example of frontier AI models being deployed in wet-lab-adjacent scientific research contexts.
OpenAI reasoning model helps diagnose 18 previously unsolved rare childhood genetic diseases
Researchers used an OpenAI reasoning model to assist physicians in diagnosing rare genetic diseases in children, identifying 18 new diagnoses in cases that had previously gone unsolved. The announcement comes from OpenAI's official blog, positioning the work as a demonstration of reasoning model utility in high-stakes clinical settings. The result is notable as a concrete real-world application of frontier reasoning capabilities in medicine.
OpenAI Introduces Deep Research Agent
OpenAI has launched 'deep research,' an agentic capability that uses reasoning to synthesize large volumes of online information and complete multi-step research tasks autonomously. The feature is initially available to ChatGPT Pro users, with rollout to Plus and Team tiers to follow. It represents a step toward practical autonomous research agents built on OpenAI's reasoning model infrastructure.
Introducing GPT-5.2
OpenAI has released GPT-5.2, described as their most advanced frontier model for professional use, featuring state-of-the-art reasoning, long-context understanding, coding, and vision capabilities. The model is available through ChatGPT and the OpenAI API. It is positioned to support faster and more reliable agentic workflows.
Medical Research with GPT-5
OpenAI published a blog post describing how GPT-5 is being used for medical research applications. The post appears to be an announcement or case study highlighting GPT-5's capabilities in a healthcare/research context. Specific details about methods, benchmarks, or outcomes are not provided in the available text.
Introducing GPT-5.5
OpenAI has announced GPT-5.5, described as their most capable model to date, with improvements in speed and reasoning targeted at complex tasks including coding, research, and data analysis. The announcement positions GPT-5.5 as a step beyond GPT-5 in OpenAI's model lineage. The blog post is brief and announcement-level, with limited technical detail provided at this stage.